Blog

APCaRI is part of the Movember Prostate Cancer Outcomes network

The Prostate Cancer Outcomes Global Initiative to Compare and Reduce Variation is a project led by Movember aiming to improve health outcomes for men throughout their prostate cancer journey by focusing on variation in care and engaging clinicians and researchers across 14 countries worldwide.

The international team will collect data from prostate cancer patients segmented into the categories of data items as outlined by the International Consortium for Health Outcomes Measurement (ICHOM). These include patient factors, baseline tumor factors, pathological information, treatment variables, acute complications of treatment, and survival and disease control).

The Alberta Prostate Cancer dataset is highly aligned with the ICHOM standards. This means that we can effectively compare treatments and outcomes in Alberta with teams around the world to find ways to improve our care at home and abroad!

This is the result of hours of planning and true team work lead by Dr. Trafford Crump, the APCaRI Scientific and Data Quality Committee, and the APCaRI clinical, scientific, research and pathology teams. Thanks to your efforts, we are one step closer to improving patient outcomes.

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Posts

goes to...APCaRI member Russ Greiner Posted on Jun 15 21 at 7:51pm
Participation Milestone! Posted on May 29 21 at 6:12pm
Raja Singh Posted on Apr 30 21 at 12:24pm

MLA Dr. Richard Starke Toured APCaRI Labs

The APCaRI laboratory in the Department of Oncology at the University of Alberta hosted an early morning visit on October 11 by Dr. Richard Starke, MLA for Vermilion-Lloydminster @RichardStarke. Dr. John Lewis led the tour of the facility and discussed the work being done by APCaRI members on using the in vivo chick embryo imaging technique to follow tumour motility through the vasculature, screening for metastasis-gene targets in human cancers to develop metastasis-blocking therapeutics, and the design of Nanostics’ prostate cancer diagnostic blood tests platform; ClarityDx Prostate. Later that day Richard Starke tweeted about his visit describing it as an incredible tour of @UAlberta research facilities!
Along with Dr.’s Starke and Lewis (from left to right in feature photo above) were technicians Mike Wong and Diana Pham, Nanostics COO Catalina Vasquez, technician Renjith Pillai and our Program manager Rume Djebah.

- Perrin Beatty